✦ LIBER ✦

The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation

✍ Scribed by T. Uematsu; M. Nakano; K. Kosuge; M. Kanamaru; M. Nakashima

Publisher: Springer
Year: 1993
Tongue: English
Weight: 367 KB
Volume: 44
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00316473

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The pharmacokinetics of theβ2-adrenocept

The pharmacokinetics of theβ2-adrenoceptor agonist fenoterol in healthy women

✍ K. Warnke; R. Hildebrandt; K. Günther; U. Langen; U. Gundert-Remy 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 279 KB

Electrophysiological effects mediated by

Electrophysiological effects mediated by the stimulation of cardiac β2-adrenoceptors with tulobuterol

✍ Alessandro Mugelli; Sandra Amerini; Paolo Bonfioli Cavalcabo; Elisabetta Cerbai; 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 541 KB

Synthesis of the Marine Sponge Derived β

Synthesis of the Marine Sponge Derived β2-Adrenoceptor Agonist S1319.

✍ Robin A. Fairhurst; Diana Janus; Annabel Lawrence 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 9 KB

Efficacy is a contributing factor to the

Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled β2-adrenoceptor agonists

✍ Elizabeth M. Rosethorne; Robert J. Turner; Robin A. Fairhurst; Steven J. Charlto 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 262 KB

Diuretic-related hypokalaemia: the role

✍ P. Widmer; R. Capaul; U. Mueller; R. Galeazzi; R. Maibach; U. P. Künzi; R. Hoign 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 685 KB

All 5,047 consecutive inpatients admitted to the Internal Medicine Division of a teaching hospital (Zieglerspital, Berne) between 1982 and 1985 were registered in accordance with the CHDM (Comprehensive Hospital Drug Monitoring) questionnaire of adverse drug reactions (ADRs). Of them, 2,439 were tre

Inhalation by design: Dual pharmacology

Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

✍ Lyn H. Jones; Helen Baldock; Mark E. Bunnage; Jane Burrows; Nick Clarke; Michele 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 877 KB

This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of 'inhalation by design'. A key feature of this work is the combination of balanced potency and pharmacodynam